BioCentury | Aug 15, 2018
Emerging Company Profile

Breaking bad biofilms

Synspira LLC is developing glycopolymers against pulmonary disorders by targeting three mechanisms that exacerbate pulmonary decline: bacteria themselves, the mucus and biofilms that protect them and inflammation that leads to lasting tissue damage. Synspira in-licensed...
BioCentury | Feb 16, 2018
Clinical News

Alopexx reports Phase I data for bacterial infection prevention candidate

...Alopexx said the 75 and 150 μg doses led to increases in antibody titers against poly-N-acetyl glucosamine (PNAG)...
...a “positive indication” of protective immunity as measured by complement activation and binding to the PNAG...
...pharmacodynamics and killing of PNAG-expressing pathogens Status: Phase I data Milestone: NA Claire Quang AV3208 PNAG Vaccine Alopexx Vaccine LLC Poly-N-acetyl glucosamine (PNAG)...
BioCentury | Nov 13, 2014
Distillery Therapeutics

Indication: Infectious disease

...Licensing status Publication and contact information Infectious disease Bacterial infection Ixodes scapularis antifreeze glycoprotein (iafgp); poly-N-acetyl glucosamine (PNAG)...
...In a panel of cultured, biofilm-forming bacteria, recombinant iafgp decreased levels of the biofilm component PNAG...
...of bacterial infection. Alopexx Pharmaceuticals LLC and partner Sanofi have SAR279356, a human mAb against PNAG...
BioCentury | Nov 10, 2014
Company News

Alopexx Pharmaceuticals, sanofi-aventis deal

...to treat serious infections. Alopexx takes primary responsibility for development of the human mAb against poly-N-acetyl glucosamine (PNAG)...
BioCentury | Jun 13, 2013
Distillery Therapeutics

Indication: Infectious disease

...mouse studies suggest an anti-PNAG antibody could help prevent infections from a range of pathogens. PNAG...
...C. albicans, N. meningitidis, S. pneumoniae, S. pyogenes or P. burghei infection, pretreatment with the anti-PNAG...
...on deacetylated PNAG in preclinical development to prevent bacterial infections in humans and animals (see PNAG...
BioCentury | Jun 13, 2013
Targets & Mechanisms

Table 2: Nine out of ten for PNAG

...ten for PNAG Table 2. . Multiple studies have determined that the surface antigen poly-N-acetylglucosamine (PNAG...
...tract infections, ventilator-associated pneumonia and surgical-site infections. Source: Refs. 1,10,13,15; Alopexx Vaccine LLC Pathogen Type PNAG...
...Acinetobacter baumannii Bacteria Yes15 3 K. oxytoca Bacteria Yes 2 AIndicates whether the pathogen expresses PNAG...
BioCentury | Jun 13, 2013
Targets & Mechanisms

PNAG: broadening infection protection

...team investigated whether PNAG was expressed on bacteria and other pathogens in which the four-gene PNAG-producing...
...of ten for PNAG"). "This implies that a PNAG vaccine or passive immunotherapy with the anti-PNAG...
...protection: Table 1: Adding pathogens to the PNAG list Table 1. Adding pathogens to the PNAG...
BioCentury | Apr 2, 2012
Emerging Company Profile

Arsanis: Antibodies for infection

...KaloBios Pharmaceuticals Inc. and the VivaScreen discovery technology from Vivalis S.A. SAR279356, a mAb against poly-N-acetyl glucosamine (PNAG)...
BioCentury | Dec 14, 2009
Company News

Alopexx Pharmaceuticals, sanofi-aventis deal

...granted sanofi-aventis an option to license exclusive, worldwide rights to F598 . The mAb against poly-N-acetyl glucosamine (PNAG)...
BioCentury | Dec 11, 2009
Company News

sanofi receives option to Alopexx mAb

...Euronext:SAN; NYSE:SNY) an option to license exclusive, worldwide rights to F598 . The mAb against poly-N-acetyl glucosamine (PNAG)...
Items per page:
1 - 10 of 10